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Abstract
The aim was to assess whether fibroblast growth factor 21 (FGF-21) and adiponectin influence intrahepatic 
cholestasis of pregnancy (ICP) pathogenesis and whether ursodeoxycholic acid (UDCA) has an impact on their 
levels. 50 pregnant women with ICP (ICP PW), 50 with uncomplicated pregnancy (HPW) and 50 healthy nonpreg-
nant women (HW) were included. In ICP PW the first blood sample was drawn at the time of diagnosis, while in 
HPW it was drawn in the 28th week of pregnancy. The next blood samples were drawn in the 32nd and 36th week 
of pregnancy and one day after delivery. UDCA was administered when ICP was diagnosed. In ICP PW serum 
FGF-21 concentration was the lowest at the time of diagnosis with an evident increase after UDCA administra-
tion. Serum FGF-21 levels were significantly higher in ICP PW than in HPW from the first to the last measurement. 
There was a negative association between adiponectin and bile acids (BAs) levels in the later stage of pregnancy 
in ICP PW. Up-regulated FGF-21 serum levels in ICP patients compared to HPW persisted after delivery, suggest-
ing its role in disease pathophysiology. The negative association between serum adiponectin and BAs of the later 
stage of pregnancy may suggest its role in regulation of BAs concentration. UDCA exerts a beneficial effect on 
insulin sensitivity and up-regulates FGF-21 in ICP.
Key words: adiponectin, fibroblast growth factor 21, insulin resistance, intrahepatic cholestasis of pregnancy, 
ursodeoxycholic acid, bile acids.
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Introduction
Intrahepatic cholestasis of pregnancy (ICP), also 
known as obstetric cholestasis or hepatosis gestationa-
lis, is the most common pregnancy-specific liver disease 
and the second most frequent cause of jaundice in preg-
nancy following viral hepatitis. This reversible form of 
cholestasis is characterized by otherwise unexplained 
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pruritus present in the late second or third trimester and 
an elevated serum total bile acids (TBAs) level, as well as 
abnormal liver tests. All of the symptoms and signs usu-
ally spontaneous resolve rapidly after the delivery of the 
fetus [1, 2]. Depending on the ethnicity and geographic 
location the frequency of ICP varies remarkably between 
0.1% and 25%. It is observed in 0.4-1% of pregnancies in 
most areas of Europe, with a higher incidence in Scan-
dinavian countries (1.5% in Sweden). The frequency of 
ICP is also higher in South Asian (0.8-1.46%) and South 
American populations [2-4]. The etiology of ICP is still 
not completely explicit; most of the publications empha-
size the complex and multifactorial character of this con-
dition. Hepatitis C virus (HCV) infection, advanced age, 
multiple gestations, and low selenium and vitamin D 
levels have been demonstrated as risk factors of ICP in 
several studies [3, 5]. It is suggested that pathogenesis 
includes a combination of hormonal and environmen-
tal factors superimposing on a  genetic predisposition. 
The maternal course of ICP is mostly benign, except an 
aggravating pruritus, without any severe long-term com-
plications. Although it does not present a direct threat 
to the mother’s life, it is associated with the possibility 
of chronic placental insufficiency. ICP is associated with 
increased risk of fetal complications, such as intrauterine 
fetal distress, preterm labor and sudden intrauterine fetal 
demise. Furthermore, it can lead to increased frequency 
of meconium staining of amniotic fluid, cardiotocogra-
phy (CTG) abnormalities and respiratory distress syn-
drome (RDS) [3, 6, 7]. An early and accurate diagnosis 
with an appropriate medical intervention is mandatory 
for an improved fetal prognosis. As a first line treatment 
to reduce maternal pruritus and decrease laboratory 
abnormalities ursodeoxycholic acid (UDCA) is recom-
mended in a dose of 10-15 mg/kg/day [8].
Fibroblast growth factor 21 (FGF-21), a  peptide 
hormone and a  member of the FGF superfamily, has 
emerged as an important endocrine metabolic regulator 
with physiological effects on glucose and lipid metabo-
lism. It is mainly produced in the liver and in smaller 
amounts by several metabolically active tissue organs, 
such as adipose tissue, skeletal muscle, and pancreas [9, 
10]. Fasting and starvation are the main factors increas-
ing expression of FGF-21 in plasma and liver under the 
control of the nuclear receptor peroxisome prolifera-
tor-activated receptor α (PPARα) [11-13]. FGF-21 regu-
lates the energy balance through both the central nervous 
system (CNS) control of food intake and adaptation of 
hepatic, adipose tissue, and possibly pancreatic metabo-
lism to fasting-feeding periods. If FGF-21 expression is 
stimulated under fasting conditions; it induces hepatic 
gluconeogenesis [13]. Several studies have demonstrated 
metabolic benefits of administered systemically FGF-21, 
which include weight loss, improvement in glucose and 
lipid metabolism, and insulin sensitivity. FGF-21 therapy 
has been shown to increase brown adipocyte numbers, 
preserve β-cell function and mass, ameliorate hepat-
ic steatosis, reduce low-density lipoprotein cholesterol 
(LDL-C), and elevate high-density lipoprotein choles-
terol (HDL-C) [9, 12]. Fasting plasma levels of FGF-21 
are low in healthy subjects. Increased levels of FGF-21 
are observed commonly in diseases characterized by the 
accumulation of ectopic fat in the liver and dysregulation 
of adipose tissue metabolism [14, 15].
Adiponectin is a 30 kDa multimeric protein produced 
and secreted almost exclusively by adipose tissue, but also 
expressed in other tissues including liver parenchyma 
cells, human osteoblasts, epithelial cells, myocytes and 
placental tissue [16]. In serum, this adipokine occurs 
in three forms: trimers, hexamers and high-molecular 
weight (HMW) multimers, which is the most biologi-
cally active isoform [17]. Adiponectin effects are medi-
ated almost exclusively by adiponectin receptors, which 
occur as two isoforms (AdipoR1 and AdipoR2), but 
also another receptor has been identified for adiponec-
tin, called T-cadherin. It acts as a receptor for hexameric 
and HMW forms of adiponectin but not for other forms 
[16, 18]. Adiponectin demonstrates insulin-sensitizing, 
vascular-protective and anti-inflammatory properties 
[19]. Adiponectin strongly inhibits hepatic glucose pro-
duction, acting locally in key metabolic tissues, promotes 
insulin sensitization, and enhances the oxidation of free 
fatty acids in skeletal muscles. It has a protective effect on 
the body’s functioning by inhibiting cell death, decreasing 
inflammation and increasing cell survival [19].
Taking into account the main role of FGF-21 and adi-
ponectin in the physiological process and pathophysio-
logical condition, the aim of our study was to assess 
whether FGF-21 and adiponectin influence ICP patho-
genesis and whether UDCA has an impact on their levels.
Experimental section
The study was performed on 50 pregnant women 
with ICP (ICP PW). The term ICP was used if the se-
rum bile acids (BAs) level was ≥ 10 μmol/l with con-
comitant pruritus which could not be explained by 
any other conditions. Patients with ICP were aged 32.0 
(28.25-34.0) years, with body mass index (BMI) 28.4 
(24.26-30.1) kg/m2. We compared the study group 
with 1) a group of 50 healthy, pregnant women without 
ICP (HPW), age 26.0 (21.0-30.0) years and BMI 22.1 
(20.61-27.49) kg/m2, and 2) a group of 50 healthy non-
pregnant women (HW), age 31.5 (24.5-39.5) years and 
BMI 26.3 (24.37-26.99) kg/m2. We excluded patients 
and healthy pregnant women with no permission for 
contribution in research, incomplete data, fetal con-
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genital anomalies, multiple pregnancies, HELLP syn-
drome (hemolysis, elevated liver enzymes, and a  low 
platelet count syndrome), insulin dependent diabetes 
mellitus, malignancies, chronic heart failure, chronic 
kidney disease, psychiatric disorders, any alcohol con-
sumption, or thyroid disorders. The exclusion criteria 
were also abnormal transaminases and cholestatic en-
zymes, viral hepatitides, symptomatic cholelithiasis, 
cholecystitis, primary sclerosing cholangitis (PSC), 
primary biliary cholangitis (PBC), autoimmune hepa-
titis (AIH), Wilson’s disease, α1-antitrypsin deficiency, 
cytomegalovirus or Epstein-Barr virus infection, acute 
fatty liver of pregnancy, drug-induced liver disease and 
HIV infection. Additional exclusion criteria for HPW 
were abnormal transaminases and cholestatic enzymes 
activities. The exclusion criteria for the group of 50 HW 
were as mentioned above but also alcohol consumption 
of more than 20 g/day. The assessed clinical and labora-
tory parameters in all groups are presented in Table 1.
All parameters in pregnant women were mea-
sured at four time points in fasting condition. In ICP 
PW the first blood sample was drawn at the time of 
diagnosis. The next two blood samples were drawn in 
the 32nd and 36th week of pregnancy on UDCA treat-
ment at the dose 13-15 mg/kg and the last one day af-
ter delivery. Among HPW parameters were measured 
at 28th, 32nd and 36th week of pregnancy, while the last 
blood sample was drawn one day after the labor. In 
HW the blood sample was taken once.
The remaining biochemical parameters were mea-
sured using routine methods. The upper limit of nor-
mal (ULN) for ALT activity was set at 38 IU/l and for 
AST at 40 IU/l. Insulin resistance (IR) was calculated 
according to the homeostasis model assessment for 
IR (HOMA-IR) by the formula: fasting insulin level 
(mUI/l) × fasting glucose level (mg/dl)/405.
The study was approved by the Ethical Commit-
tee of the Silesian Medical University in Katowice 
No. KNW/0022/KB1/45/I/15, dated 29.09.2015 and 
conformed to the ethical guidelines of the Declara-
tion of Helsinki. Informed consent was obtained for 
the whole study series.
The statistical analysis was performed with 
STATISTICA 10.0 (StatSoft Polska Sp. z  o.o., Cracow, 
Poland). The data were expressed as median (25% 
quartile-75% quartile) or mean ± standard deviation. 
The Shapiro-Wilk test was used to evaluate the distribu-
tion. The statistical significance of the difference in stud-
ied variables was tested using the Mann-Whitney U-test 
and ANOVA rank Kruskal-Wallis tests for independent 
groups. Correlations were analyzed with the Spearman 
rank correlation coefficient. Statistical significance was 
defined as values of p < 0.05.
Results
Baseline characteristics and laboratory data  
of ICP PW, HPW and HW
The baseline characteristics and laboratory data 
of the study group ICP PW, HPW and HW after first 
measurement are shown in Table 1.
Comparison of FGF-21, adiponectin, BAs levels 
and other laboratory parameters at different 
time points in ICP PW
Serum FGF-21 concentration was significantly lower 
at the time of diagnosis compared to the last measurement 
[0.18 (0.15-0.48) vs. 17.3 (0.49-50.22) ng/ml, p = 0.04). 
There was however no significant increase in FGF-21 lev-
els after UDCA administration in the 32nd and 36th week 
compared to the first measurement (Table 2). No signif-
icant difference was observed in serum adiponectin lev-
els between subsequent measurements among ICP PW. 
Serum BAs levels decreased after UDCA introduction, 
but the difference reached statistical significance only 
between the first and third measurement [32.8 (24.43-
45.5) vs. 21.0 (16.15-31.03) μmol/l, p = 0.04). Fasting in-
sulin level was the highest at the time of diagnosis and 
was significantly lower in the next measurements [11.0 
(5.75-16.60) vs. 7.77 (5.84-19.22) vs. 5.30 (4.99-6.03) vs. 
5.32 (4.98-7.80) mIU/ml) in ICP PW group. Also HO-
MA-IR was the highest at the first time point with signifi-
cant depletion in subsequent measurements after UDCA 
administration.
Comparison between ICP PW and HPW  
at different time points
Serum FGF-21 levels were significantly higher in 
ICP PW in the first, third and last measurement when 
compared the same time period in HPW. After UDCA 
administration the difference was even more visible and 
still statistically significant (Table 3). There was no dif-
ference in serum adiponectin concentration between 
ICP PW and HPW at any time point. Serum BAs lev-
els were significantly higher in ICP PW in all measure-
ments compared to HPW (p < 0.001, p < 0.001, p = 0.002, 
p = 0.003, respectively). The same findings were ob-
served with respect to alanine transaminase (ALT) and 
aspartate transaminase (AST) activities (Table 3). 
Comparison between HW and ICP PW 
We also compared ICP PW with HW (Table 4). 
There was no difference in FGF-21 concentration be-
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tween HW and the first measurement in ICP PW. How-
ever, FGF-21 concentrations after up- regulation at the 
next measurements in ICP PW appear to be significant-
ly higher than in HW. There was no difference in adi-
ponectin levels between HW and ICP PW at any time 
point. HOMA-IR was significantly higher in ICP PW 
Table 1. Baseline characteristics and laboratory data of ICP PW, HPW and HW after first measurement
Parameter HW 
(n = 20)
ICP PW 1 
(n = 26)
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at the first and second measurements. However, after 
a decrease of HOMA-IR in ICP PW as of the 36th week 
the difference was not significant any more. Serum BAs 
concentration and ALT and AST activities were signifi-
cantly higher in ICP PW than in HW.
Comparison between HW and HPW
Surprisingly, FGF-21 serum concentration was 
significantly higher in HW than in HPW. There was 
no difference in adiponectin serum concentration. 
HOMA-IR was significantly higher at the 28th week of 
pregnancy, with a  subsequent decrease in HPW. BAs 
levels in HPW although significantly lower than in ICP 
PW were still significantly higher than in HW (Table 5).
Correlations between analyzed parameters
In the study we found a  significant negative cor-
relation of adiponectin with BAs in the group of ICP 
Table 2. Comparison of laboratory parameters, HOMA-IR, FGF-21 and adiponectin levels at successive time points in ICP PW 

























































































Comparison between subgroups among ICP PW (p-value)
Parameter ICP PW 1/ 
ICP PW 2
ICP PW 1/ 
ICP PW 3
ICP PW 1/ 
ICP PW 4
ICP PW 2/ 
ICP PW 3
ICP PW 2/ 
ICP PW 4
ICP PW 3/ 
ICP PW 4
ALT (IU/l) 0.36 0.45 0.81 0.55 0.22 0.51
AST (IU/l) 0.31 0.07 0.29 0.36 0.87 0.68
Bilirubin (mg/dl) 0.56 1 0.64 0.38 0.24 0.76
Alkaline phosphatase (IU/l) 0.97 0.70 0.75 0.60 0.53 1
GGTP (IU/l) 0.91 0.24 0.37 0.23 0.43 0.99
Fasting glucose (mg/dl) 0.21 0.11 0.22 0.002 0.01 0.69
Bile acids (μmol/l) 0.09 0.04 0.11 0.51 0.89 0.69
Fasting insulin (mIU/ml) 0.10 0.01 0.01 0.02 0.09 0.76
Adiponectin (ng/ml) 0.82 0.06 0.18 0.13 0.31 0.78
FGF-21 (ng/ml) 0.21 0.09 0.04 0.73 0.73 0.37
HOMA-IR 0.86 0.02 0.04 0.02 0.07 0.81
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PW at the third and last measurement (r = [–0.61], 
p < 0.05 and r = [–0.85], p < 0.01, respectively). Adi-
ponectin and FGF-21 did not show any other statis-
tically significant correlation with liver function tests, 
fasting insulin, blood sugar, HOMA-IR or lipid profile 
in any group.
Table 3. Comparison of laboratory parameters, HOMA-IR, FGF-21 and adiponectin levels between ICP PW and HPW at different time points
































































































































































































Comparison between ICP PW and HPW (p-value)
 Parameter ICP PW 1/HPW 1 ICP PW 2/HPW 2 ICP PW 3/HPW 3 ICP PW 4/HPW 4
ALT (IU/l) 0.01 < 0.001 0.01 0.02
AST (IU/l) 0.004 < 0.001 0.02 0.11
Bilirubin  
(mg/dl)




0.10 0.24 0.54 0.61
GGTP (IU/l) 0.30 0.43 0.06 0.19
Fasting glucose 
(mg/dl)
0.13 0.01 0.04 0.12
Bile acids 
(μmol/l)
< 0.001 < 0.001 0.002 0.003
Fasting insulin 
(mIU/ml)
0.45 0.10 0.09 0.28
Adiponectin 
(ng/ml)
0.37 0.21 0.51 0.91
FGF-21 (ng/ml) 0.03 0.04 0.01 0.03
HOMA-IR 0.79 < 0.001 0.15 0.35
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Table 4. Comparison between ICP PW and HW
Parameter HW ICP PW 1 ICP PW 2 ICP PW 3 ICP PW 4
























































































Comparison between ICP PW and HW (p-value)
Parameter ICP PW 1/HW ICP PW 2/HW ICP PW 3/HW ICP PW 4/HW
ALT (IU/l) < 0.001 < 0.001 0.003 0.004
AST (IU/l) < 0.001 < 0.001 < 0.001 0.003
Bilirubin (mg/dl) 0.30 0.05 0.13 0.33
Alkaline phosphatase (IU/l) < 0.001 < 0.001 < 0.001 < 0.001
GGTP (IU/l) 0.76 0.69 0.51 0.52
Fasting glucose (mg/dl) 0.33 0.06 1.00 0.76
Bile acids (μmol/l) < 0.001 < 0.001 < 0.001 < 0.001
Fasting insulin (mIU/ml) 0.08 0.24 0.11 0.22
Adiponectin (ng/ml) 0.67 0.57 0.80 1.00
FGF-21 (ng/ml) 0.55 0.52 0.74 0.35
HOMA-IR 0.04 0.03 0.89 0.96
Discussion
As mentioned before, FGF-21 has been suggested to 
be an important regulator of energy metabolism hav-
ing beneficial effects on glucose and lipid metabolism. 
FGF-21 expression is altered in patients with metabol-
ic diseases, including metabolic syndrome, obesity, or 
type 2 diabetes [19]. Not only pathological phenome-
na influence this adipokine expression as well as serum 
circulating level, but also it is modified by physiological 
condition such as pregnancy, which is probably associ-
ated with the attempt to maintain metabolic homeosta-
sis. Research performed on a mouse model as well as 
among pregnant women showed that plasma FGF-21 
was significantly increased among study groups in com-
parison to non-pregnant controls [20, 21]. In contrast, 
the results of our study showed significantly lower levels 
of FGF-21 among HPW in comparison to HW. More-
over, these disparities were noticeable in subsequent 
measurements, even after delivery. According to our 
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results, serum FGF-21 concentration was significantly 
lower in ICP PW at the time of diagnosis compared to 
successive measurements. The increased FGF-21 level 
was stable from the 2nd to 4th measurement on UDCA 
treatment.
Formerly, FGF-21 was investigated as a  serum 
marker of pregnancy related pathologies such as 
preeclampsia (PE) or gestational diabetes mellitus 
(GDM). Stepan et al. [22] reported median mater-
nal FGF-21 serum concentrations to be almost three 
times higher in PE patients as compared to healthy, 
age-matched pregnant women (309.6 vs. 105.2 ng/l, 
p < 0.001). Similarly, GDM is associated with a signif-
icant increase of this hepatokine serum concentration 
[23]. That easily leads us to the question: is there a pos-
sibility that FGF-21 plays a  role in ICP pathogenesis? 
Based on our knowledge, this study is the first to try 
to answer this question. According to the results, se-
rum FGF-21 levels were significantly higher in patients 
with ICP compared with healthy pregnant women. To 
fully understand how this hepatokine may influence 
pathophysiology of ICP, it is essential to analyze step 
Table 5. Comparison between HW and HPW
Parameter HW HPW 1 HPW 2 HPW 3 HPW 4
























































































Comparison between HW and HPW (p-value)
 Parameter HW/HPW 1 HW/HPW 2 HW/HPW 3 HW/HPW 4
ALT (IU/l) 0.76 0.66 0.64 0.91
AST (IU/l) 0.05 0.03 0.01 0.03
Bilirubin (mg/dl) 0.01 0.01 0.02 0.11
Alkaline phosphatase (IU/l) 0.02 0.003 < 0.001 0.01
GGTP (IU/l) 0.37 0.52 0.01 0.05
Fasting glucose (mg/dl) 0.28 0.34 0.30 0.33
Bile acids (μmol/l) < 0.001 < 0.001 0.002 0.003
Fasting insulin (mIU/ml) 0.45 0.10 0.09 0.28
Adiponectin (ng/ml) 0.37 0.21 0.51 1.00
FGF-21 (ng/ml) 0.03 0.06 0.006 0.03
HOMA-IR 0.79 < 0.001 0.15 0.35
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by step the mechanism of BAs synthesis and the role 
of FGF-21 in regulating that process. Zhang et al. [24] 
proved that overexpression of FGF-21 in mice leads to 
increased BAs synthesis and pool size. Further, the au-
thors showed that adipokine regulates BAs metabolism 
indirectly by interfering with physiological inhibition 
of BAs synthesis via another member of the FGF sub-
family, FGF-15/19 [24]. It is well established that FGF-
15/19 indirectly reduces the serum BAs concentration 
[25, 26]. FGF-15/19 acts in the liver via the βKlotho/
FGFR4 complex. Due to the competition between FGF-
15/19 and FGF-21 for access to βKlotho, each increase 
of FGF-21 concentration reverses the inhibition of 
BAs synthesis by acting as an antagonist to FGF-15/19 
function. The same study highlights the possible role of 
FGF-21 in BAs metabolism by its influence on the ex-
pression of hepatic and ileum membrane transporters, 
which play critical roles in maintaining BAs homeosta-
sis. Nevertheless, this finding seems to be a secondary 
factor in increasing the circulating BAs pool size. Ac-
cording to all of the information presented above, we 
could suppose that significantly higher serum concen-
tration of FGF-21 among ICP PW contrary to HPW 
in our research could be one of the main factors in 
ICP pathogenesis, since elevation of TBAs level is one 
of the diagnostic criteria of ICP. Furthermore, the fact 
that increased concentration of FGF-21 persisted after 
delivery suggests that elevation may not be just a tran-
sient, but rather an overall predisposition to cholestasis 
among ICP women.
Nonetheless, we have to emphasize the fact that 
there was no correlation between levels of FGF-21 and 
TBAs among the study group, inasmuch as a decrease 
of TBAs did not reflect the fluctuations of serum cir-
culating FGF-21. If we analyze changes of serum BAs 
level, we could noticed the only significant difference 
in BAs concentration between first and third mea-
surements without further decrease. If a trend test is 
performed and the result is significant, a trend can be 
reported. Otherwise, the description of a tendency re-
mains unscientific. This tendency could be explained 
by treatment with UDCA, which was administered 
just after the diagnosis. UDCA has been proved to 
be effective for cholestatic diseases therapy, including 
ICP, not only due to the alleviation of pruritus, but also 
the improvement of biochemical liver tests and reduc-
tion of serum BAs levels [19, 27]. According to several 
studies [28, 29] the reduction of BAs level is associated 
with the induction of key hepatobiliary transport pro-
teins by UDCA. There is an evident difference between 
UDCA and FGF-21 with respect to the mechanism 
they play in BAs metabolism. While FGF-21 indirectly 
enhances synthesis of BAs, UDCA facilities their hepa-
tobiliary transport. In view of the above information, 
the role of FGF-21 in the ICP pathogenesis cannot be 
excluded. The lack of correlation between adipokine 
and BAs levels among ICP PW could be explained by 
the deranging influence of UDCA treatment.
To the best of our knowledge this is the first study 
which takes into consideration the relation between 
Serum FGF-21 levels were significantly higher in ICP PW than 
in HPW.
The negative association between serum adiponectin and BAs 
in the later stage of pregnancy may suggest adiponectin to 
play a role in regulation of BAs concentration in ICP.
UDCA exerts a beneficial effect on insulin sensitivity and 
up-regulates FGF-21 in ICP.
Fig. 1. The potential role of adiponectin and FGF-21 in intrahepatic cholestasis of pregnancy (ICP)
FGF-21 and adiponectin impacted ICP.
In ICP pregnant women serum FGF-21 concentration 
was the lowest at the time of diagnosis with an evident 
increase after UDCA administration. 
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ICP and adiponectin serum levels. Both ICP and 
changes in adiponectin expression and serum levels 
are related to metabolic disorders – dyslipidemia and 
glucose intolerance, first as a complication, and the lat-
ter as another factor playing a role in pathogenesis of 
these abnormalities.
In order to better understand the pathophysiology 
of metabolic disorders in ICP, firstly we have to retrace 
changes of glucose homeostasis in normal pregnancy. 
During normal pregnancy glucose metabolism and 
insulin production alter and lead to insulin resistance 
(IR), causing physiological maternal postprandial hy-
perglycemia. However, the mechanism responsible for 
IR has not been stated clearly. Some reports showed 
the correlation of longitudinal changes in IR with cy-
tokines and adipokine concentration [30, 31]. Preg-
nancy-associated IR is reflected in higher HOMA-IR 
levels, which we can clearly observe also in the results 
of the present study. In comparison to HW, HOMA-IR 
was significantly higher at the 28th week of pregnancy, 
with a  subsequent decrease in HPW. An association 
between ICP and glucose intolerance and dyslipidemia 
has been previously reported. Previous studies have 
shown that the incidence of GDM is higher in women 
predisposed to developing ICP and proved the rela-
tion between these two [32, 33]. A prospective study 
performed by Martineau et al. [33] on ICP patients 
showed significantly higher fasting total cholester-
ol, LDL cholesterol, serum triglycerides and reduced 
HDL cholesterol compared to those with uncomplicat-
ed pregnancy. Treatment with UDCA did not appear 
to have any influence on glucose or lipids in ICP wom-
en in this study. Despite the fact that Martineau’s study 
indicates the lack of modification of glucose or lipid 
parameters via UDCA, some of the studies presented 
a  potential effect on metabolic parameters. The me-
ta-analysis performed by Sánchez-García et al. [34] re-
vealed a significant reduction of fasting glucose levels 
following UDCA therapy. It also indicated a significant 
reduction of glycated hemoglobin (HbA1c) concen-
trations. According to results presented in our study 
HOMA-IR was the highest at the first time point with 
significant depletion in subsequent measurements 
after UDCA administration. Simultaneously, fasting 
insulin level was the highest at the time of diagnosis 
and was significantly lower in the next measurements 
among ICP PW. These results may indicate the poten-
tial positive influence of UDCA treatment on IR. Fur-
thermore, HOMA-IR was significantly higher in ICP 
PW than in HW at the first and second measurements. 
However, after the decrease of HOMA-IR in ICP PW as 
of the 36th week the difference was not significant any 
more, which may also suggest a  beneficial impact of 
UDCA therapy. Although the underlying mechanisms 
by which UDCA ameliorates glucose metabolism are 
unclear, some of the researchers have tried to discover 
an explanation. It was proved that UDCA treatment 
decreases hepatic IR through reduction of hepatic 
glucose production, resulting in the improvement of 
hyperglycemia and hyperinsulinemia [34]. It also re-
duces serum levels of tumor necrosis factor α (TNF-α), 
a pro-oxidant cytokine that promotes IR [35].
Hypoadiponectinemia is strongly correlated with 
occurrence of states associated with IR, including obe-
sity, type 2 diabetes and GDM [36]. In obesity and type 2 
diabetes, low plasma adiponectin concentrations are 
related to the degree of hyperinsulinemia and the se-
verity of IR.
Pointing to the results of some studies which as-
sessed serum adiponectin in pregnancy the inter-
pretation of our results may be vague. Pregnancy is 
characterized by multiple modifications in the wom-
an’s physiology, including alteration in hormone and 
adipokine secretion. According to Catalano et al. [37] 
in uncomplicated pregnancy total plasma adiponectin 
was found to be decreased in late pregnancy compared 
with pre-gravid measurements. Additionally, pro-
gression of pregnancy was associated with a stepwise 
lowering of plasma adiponectin level, as it was found 
previously in mice [38]. Our results did not show any 
significant difference in adiponectin levels between 
ICP PW and HPW and HW. Moreover, there was no 
significant difference in adiponectin level in ICP PW 
at the time of disease onset and the later stage of preg-
nancy.
Up to now serum adiponectin has not been inves-
tigated in ICP. The study by Salman et al. [39] scru-
tinized secretion of adiponectin in cirrhotic patients 
and cirrhotic and cholestatic patients. The results 
proved that adiponectin level was significantly high-
er in cirrhotic patients in comparison to controls. 
Furthermore, this elevation was more pronounced in 
patients with intercurrent cirrhosis and cholestasis. 
Adiponectin level was also associated with laboratory 
markers of cholestasis (alkaline phosphatase, GGTP) 
and serum bilirubin level. In contrast to our study, Sal-
man et al. found that adiponectin level is linked to the 
degree of hepatocellular injury and cholestasis. Addi-
tionally, adiponectin levels in cirrhosis were not relat-
ed to parameters of body composition or metabolism 
but exclusively to reduced liver function. However, it 
is crucial to emphasize that the underlying etiology of 
liver cirrhosis and cholestasis in Salman’s patients was 
chronic hepatitis C, which potentially had a substan-
tial influence on the disparities between the results.
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Similar conclusions to Salman’s investigation were 
drawn from the study performed by Floreani et al. 
[40], which proved that adiponectin was significant-
ly higher in patients with primary biliary cholangi-
tis (PBC) than in healthy controls. Another study by 
Tacke et al. [41] showed adiponectin to be increased in 
chronic liver disease of different etiology compared to 
controls. It is essential to note that patients with biliary 
or autoimmune chronic liver diseases had significantly 
higher adiponectin concentrations. Furthermore, the 
study also found a  positive correlation between adi-
ponectin and parameters indicating cholestasis, e.g. 
alkaline phosphatase, BAs, GGTP and bilirubin. These 
findings suggested that reduced biliary exertion of ad-
iponectin in cholestatic liver disease may contribute to 
its increased concentrations in plasma.
Therefore this raises the question: what is the rea-
son for the lack of significant adiponectin increase 
among ICP patients? Presumably, it is associated with 
different pathogenesis of cholestasis in ICP, develop-
ment of which is connected with reduction of hepatic 
biliary transport proteins’ expression and through in-
ternalization of the bile salt export pump (BSEP), and 
genetic defects in other canalicular transporters a cel-
lular level [3] rather than the obstructive mechanism 
of cholestasis presented in the mentioned studies. 
However, another finding of our study is that serum 
adiponectin levels were negatively associated with BAs 
levels in the last two measurements in ICP PW. It may 
suggest adiponectin to play a role in down-regulation 
of BAs levels. However, this aspect must be confirmed 
in further studies.
The low number of patients may be considered 
a  limitation of this study, but it enabled us to retain 
homogeneity of the compared groups, simultaneously. 
Moreover, the lack of GDM patients with ICP among 
the analyzed groups prevented us from assessing the 
influence of this factor on the levels of FGF-21 and es-
pecially adiponectin. Additionally, our study does not 
include the assessment of body composition, includ-
ing fat mass, which imposes a negative impact on adi-
ponectin concentration.
To the best of our knowledge, our data are the first 
to show up-regulated FGF-21 serum levels in ICP pa-
tients compared to healthy pregnant women, which 
may suggest the role of FGF-21 in the pathophysiol-
ogy of ICP. Additionally, the fact that increased con-
centration of FGF-21 persisted after delivery suggests 
that the hepatokine may be a predisposing factor for 
ICP. On the other hand, the negative association be-
tween serum adiponectin and BAs in the later stage of 
pregnancy may suggest adiponectin to play a role in 
regulation of BAs concentration in ICP. UDCA exerts 
a beneficial effect on insulin sensitivity and up-regu-
lates FGF-21 in ICP. 
We believe that further, more complex research will 
enable to clarify the role of adiponectin and especially 
FGF-21 in the pathogenesis of ICP, which may have 
a  positive impact on diagnosis and treatment of this 
condition in the future (Fig. 1).
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